Literature DB >> 21436319

Antifungal medication is efficient in the treatment of sarcoidosis.

Marjeta Tercelj1, Barbara Salobir, Mirjana Zupancic, Ragnar Rylander.   

Abstract

OBJECTIVES: Fungi have been suspected of contributing to the pathogenesis of sarcoidosis. A previous intervention study demonstrated an improvement in the clinical condition in 15 out of 18 patients with a long-term history of sarcoidosis when antifungal medication was added to corticosteroids. The present study was performed to compare the effects of antifungal treatment with corticosteroid treatment in sarcoidosis.
METHODS: Patients with newly diagnosed sarcoidosis were recruited. Corticosteroids were given to 39 subjects, corticosteroid + antifungal to 31, and antifungal only to 22 subjects. The effects of the treatments were evaluated at 6 months. X-ray scores were measured before and after treatment together with pulmonary diffusion capacity and two markers of sarcoidosis activity, that is, angiotensin-converting enzyme in serum (sACE) and chitotriosidase (CTO).
RESULTS: X-ray scores as well as sACE and CTO decreased significantly in all groups. The X-ray score decreased slightly more among subjects in the groups that received antifungal medication compared with corticosteroids only (p < 0.001).
CONCLUSION: The results suggest that antifungal treatment is as efficient as corticosteroid treatment against the granulomatous and inflammatory manifestations of sarcoidosis. This is probably because this treatment is directed towards the causative agent. Additional studies are required to define the phenotype, where the antifungal treatment was not efficient (4/22) and to perform long-term follow up to determine the risk of recurrence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21436319     DOI: 10.1177/1753465811401648

Source DB:  PubMed          Journal:  Ther Adv Respir Dis        ISSN: 1753-4658            Impact factor:   4.031


  9 in total

1.  In vitro and in vivo reactivity to fungal cell wall agents in sarcoidosis.

Authors:  M Terčelj; S Stopinšek; A Ihan; B Salobir; S Simčič; B Wraber; R Rylander
Journal:  Clin Exp Immunol       Date:  2011-10       Impact factor: 4.330

2.  Human chitotriosidase: a sensitive biomarker of sarcoidosis.

Authors:  Elena Bargagli; David Bennett; Claudia Maggiorelli; Pasquale Di Sipio; Maria Margollicci; Nicola Bianchi; Paola Rottoli
Journal:  J Clin Immunol       Date:  2012-08-10       Impact factor: 8.317

3.  CD4+ T cells in the lungs of acute sarcoidosis patients recognize an Aspergillus nidulans epitope.

Authors:  Johan Grunewald; Andrew P Fontenot; Sarah A Greaves; Avinash Ravindran; Radleigh G Santos; Lan Chen; Michael T Falta; Yang Wang; Angela M Mitchell; Shaikh M Atif; Douglas G Mack; Alex N Tinega; Lisa A Maier; Shaodong Dai; Clemencia Pinilla
Journal:  J Exp Med       Date:  2021-08-19       Impact factor: 17.579

Review 4.  Interleukin-12 family cytokines and sarcoidosis.

Authors:  Sabine Ringkowski; Paul S Thomas; Cristan Herbert
Journal:  Front Pharmacol       Date:  2014-10-27       Impact factor: 5.810

5.  Sarcoidosis treatment with antifungal medication: a follow-up.

Authors:  Marjeta Terčelj; Barbara Salobir; Mirjana Zupancic; Ragnar Rylander
Journal:  Pulm Med       Date:  2014-12-04

6.  The Role of Fungi in the Etiology of Multiple Sclerosis.

Authors:  Julián Benito-León; Martin Laurence
Journal:  Front Neurol       Date:  2017-10-16       Impact factor: 4.003

7.  A fungal antigenic driver for Löfgren's syndrome sarcoidosis.

Authors:  Clarice X Lim; Thomas Weichhart
Journal:  J Exp Med       Date:  2021-09-13       Impact factor: 14.307

8.  Fungal cell wall agents and bacterial lipopolysaccharide in organic dust as possible risk factors for pulmonary sarcoidosis.

Authors:  Sanja Stopinšek; Alojz Ihan; Barbara Salobir; Marjeta Terčelj; Saša Simčič
Journal:  J Occup Med Toxicol       Date:  2016-09-21       Impact factor: 2.646

Review 9.  Environmental Risk Factors for Sarcoidosis.

Authors:  Marc A Judson
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.